{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:12:43Z","timestamp":1767892363873,"version":"3.49.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1053\/j.semnuclmed.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T23:18:04Z","timestamp":1749251884000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Targets for Positron Emission Tomography Imaging in Parkinson\u00b4s Disease"],"prefix":"10.1053","volume":"55","author":[{"given":"Yu-Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuantao","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"The Lancet Neurology"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1007\/s00259-024-06803-w","article-title":"Neuroimaging biomarkers in the biological definition of Parkinson's disease and dementia with lewy bodies - EANM position on current state, unmet needs and future perspectives","volume":"51","author":"Brendel","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00259-023-06403-0","article-title":"International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism","volume":"51","author":"Tian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1474-4422(18)30169-8","article-title":"Network imaging biomarkers: insights and clinical applications in Parkinson's disease","volume":"17","author":"Schindlbeck","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/1673-5374.391180","article-title":"Recent progress in the applications of presynaptic dopaminergic positron emission tomography imaging in parkinsonism","volume":"20","author":"Yang","year":"2025","journal-title":"Neur Regenerat Res"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00259-019-04587-y","article-title":"Quantification and discriminative power of (18)F-FE-PE2I PET in patients with Parkinson's disease","volume":"47","author":"Delva","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0271678X20958755","article-title":"Simplified quantification of [(18)F]FE-PE2I PET in Parkinson's disease: discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium","volume":"41","author":"Brumberg","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2967\/jnumed.114.152421","article-title":"Quantitative analysis of (1)(8)F-(E)-N-(3-Iodoprop-2-Enyl)-2beta-carbofluoroethoxy-3beta-(4\u2032-Methyl-Phenyl) nortropane binding to the dopamine transporter in Parkinson Disease","volume":"56","author":"Fazio","year":"2015","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","article-title":"Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I","volume":"53","author":"Sasaki","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2018.05.008","article-title":"Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off","volume":"53","author":"Chung","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00415-006-0322-9","article-title":"18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages","volume":"254","author":"Wang","year":"2007","journal-title":"J Neurol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/RLU.0000000000002148","article-title":"Clinical, dopaminergic, and metabolic correlations in Parkinson Disease: a dual-tracer PET study","volume":"43","author":"Liu","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0016","article-title":"Preserved caudate function in young-onset patients with Parkinson\u2019s disease: a dual-tracer PET imaging study","volume":"12","author":"Yang","year":"2019","journal-title":"Adv Neuroimag"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.627356","article-title":"Dopaminergic and metabolic correlations with cognitive domains in non-demented Parkinson's Disease","volume":"13","author":"Han","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.parkreldis.2013.02.013","article-title":"Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging","volume":"19","author":"Wu","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102416","article-title":"Reproducible metabolic topographies associated with multiple system atrophy: network and regional analyses in Chinese and American patient cohorts","volume":"28","author":"Shen","year":"2020","journal-title":"Neuroimage Clin"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1002\/hbm.24044","article-title":"Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: multivariate and univariate analyses in American and Chinese patient cohorts","volume":"39","author":"Ge","year":"2018","journal-title":"Hum Brain Mapp"},{"issue":"Pt 12","key":"10.1053\/j.semnuclmed.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/brain\/awu290","article-title":"Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder","volume":"137","author":"Wu","year":"2014","journal-title":"Brain"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/mds.29138","article-title":"Consistent abnormalities in metabolic patterns of Lewy body dementias","volume":"37","author":"Lu","year":"2022","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.652059","article-title":"Cerebral metabolism related to cognitive impairments in multiple system atrophy","volume":"12","author":"Shen","year":"2021","journal-title":"Front Neurol"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.788166","article-title":"The frontal and cerebellar metabolism related to cognitive dysfunction in multiple system atrophy","volume":"14","author":"Shen","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13550-020-00722-1","article-title":"Metabolic network as an objective biomarker in monitoring deep brain stimulation for Parkinson's disease: a longitudinal study","volume":"10","author":"Ge","year":"2020","journal-title":"EJNMMI Res"},{"issue":"44","key":"10.1053\/j.semnuclmed.2025.05.004_bib0026","first-page":"747","article-title":"Nuclear imaging in the diagnosis of clinically uncertain parkinsonian syndromes","volume":"116","author":"Buchert","year":"2019","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s43657-022-00079-6","article-title":"Adjustment for the age- and gender-related metabolic changes improves the differential diagnosis of parkinsonism","volume":"3","author":"Lu","year":"2022","journal-title":"Phenomics"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s43657-022-00077-8","article-title":"Dopaminergic dysfunction and glucose metabolism characteristics in parkin-induced early-onset Parkinson\u2019s disease compared to genetically undetermined early-onset Parkinson\u2019s disease","volume":"3","author":"Liu","year":"2022","journal-title":"Phenomics"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41746-024-01012-z","article-title":"Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2024","journal-title":"NPJ Digit Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1017\/cjn.2022.34","article-title":"Current concepts of mixed pathologies in neurodegenerative diseases","volume":"50","author":"Forrest","year":"2023","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0031","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mds.30166","article-title":"Neuropsychological tests of memory, visuospatial, and language function in Parkinson's Disease: review, critique, and recommendations","volume":"40","author":"Bezdicek","year":"2025","journal-title":"Mov Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"6645","key":"10.1053\/j.semnuclmed.2025.05.004_bib0033","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0034","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s004010050918","article-title":"Accumulation of alpha-synuclein\/NACP is a cytopathological feature common to lewy body disease and multiple system atrophy","volume":"96","author":"Wakabayashi","year":"1998","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.737195","article-title":"The concept of alpha-synuclein strains and how different conformations may explain distinct neurodegenerative disorders","volume":"12","author":"Malfertheiner","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00441-017-2733-6","article-title":"Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with lewy bodies","volume":"373","author":"Cersosimo","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0038","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40035-021-00242-5","article-title":"Differential seeding and propagating efficiency of alpha-synuclein strains generated in different conditions","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0039","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s40478-019-0859-3","article-title":"alpha-synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb","volume":"7","author":"Rey","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00441-018-2839-5","article-title":"a-synuclein strains and seeding in Parkinson's disease, incidental lewy body disease, dementia with lewy bodies and multiple system atrophy: similarities and differences","volume":"373","author":"Peelaerts","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","article-title":"alpha-synuclein strains target distinct brain regions and cell types","volume":"23","author":"Lau","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0042","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56825","article-title":"\u03b1-synuclein strains that cause distinct pathologies differentially inhibit proteasome","volume":"9","author":"Suzuki","year":"2020","journal-title":"eLife"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0043","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/mds.27013","article-title":"Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology","volume":"32","author":"Koga","year":"2017","journal-title":"Mov Disord"},{"issue":"15","key":"10.1053\/j.semnuclmed.2025.05.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2024.05.006","article-title":"Imaging alpha-synuclein pathologies in animal models and patients with Parkinson's and related diseases","volume":"112","author":"Endo","year":"2024","journal-title":"Neuron"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0045","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"issue":"16","key":"10.1053\/j.semnuclmed.2025.05.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.06.004","article-title":"Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies","volume":"186","author":"Xiang","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-024-00787-9","article-title":"Positron emission tomography tracers for synucleinopathies","volume":"20","author":"Xiang","year":"2025","journal-title":"Mol Neurodegener"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0048","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marquie","year":"2015","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0049","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2967\/jnumed.117.194282","article-title":"(18)F-flortaucipir PET\/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease","volume":"59","author":"Nasrallah","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.05.004_bib0050","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.05.004_bib0051","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.05.004_bib0052","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the Lewy body diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0053","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0054","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1038\/s41598-018-23041-x","article-title":"(18)F-AV-1451 in Parkinson's Disease with and without dementia and in dementia with Lewy bodies","volume":"8","author":"Smith","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0055","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mds.27252","article-title":"Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases","volume":"33","author":"Lee","year":"2018","journal-title":"Mov Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00401-024-02801-2","article-title":"Association of in vivo retention of [(18)f] flortaucipir pet with tau neuropathology in corresponding brain regions","volume":"148","author":"Freiburghaus","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-023-02672-z","article-title":"Head-to-head comparison of [(18)F]-Flortaucipir, [(18)F]-MK-6240 and [(18)F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases","volume":"147","author":"Aguero","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0058","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0059","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.05.004_bib0060","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.29328","article-title":"The monoamine oxidase-B inhibitor selegiline does not affect (18) F-florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series","volume":"38","author":"Li","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0061","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.29273","article-title":"In Vivo (18) F-florzolotau tau positron emission tomography imaging in Parkinson's Disease dementia","volume":"38","author":"Tang","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0062","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mds.30055","article-title":"(18)F-Florzolotau PET imaging unveils tau pathology in dementia with Lewy bodies","volume":"40","author":"Tang","year":"2025","journal-title":"Mov Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0063","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1212\/WNL.0000000000200344","article-title":"Proteinopathy and longitudinal cognitive decline in Parkinson Disease","volume":"99","author":"Myers","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0064","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/alz.12886","article-title":"Quantification of [(18) F]florbetaben amyloid-PET imaging in a mixed memory clinic population: the ABIDE project","volume":"19","author":"Collij","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0065","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1212\/WNL.0000000000207393","article-title":"beta-amyloid load on PET along the continuum of dementia with Lewy bodies","volume":"101","author":"Diaz-Galvan","year":"2023","journal-title":"Neurology"},{"issue":"5\u20136","key":"10.1053\/j.semnuclmed.2025.05.004_bib0066","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000464322","article-title":"Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson's disease without dementia","volume":"77","author":"Mashima","year":"2017","journal-title":"Eur Neurol"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid beta, Tau, and alpha-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.05.004_bib0068","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.05.004_bib0069","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.05.004_bib0070","article-title":"PET imaging for oxidative stress in neurodegenerative disorders associated with mitochondrial dysfunction","volume":"9","author":"Ikawa","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.05.004_bib0071","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00019052-200108000-00009","article-title":"The role of glial cells in Parkinson's disease","volume":"14","author":"Vila","year":"2001","journal-title":"Curr Opin Neurol"},{"issue":"16","key":"10.1053\/j.semnuclmed.2025.05.004_bib0072","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2174\/1568026619666190708163407","article-title":"PET imaging of adenosine receptors in diseases","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0073","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1006\/exnr.1998.6993","article-title":"The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse","volume":"156","author":"Kurkowska-Jastrzebska","year":"1999","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0074","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pneurobio.2006.10.002","article-title":"The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging","volume":"80","author":"Venneti","year":"2006","journal-title":"Prog Neurobiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.05.004_bib0075","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0076","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ncpneuro0773","article-title":"Technology insight: imaging neurodegeneration in Parkinson's disease","volume":"4","author":"Brooks","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0077","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00415-021-10877-z","article-title":"Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies","volume":"269","author":"Zhang","year":"2022","journal-title":"J Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0078","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/npp.2012.255","article-title":"Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia","volume":"38","author":"Edison","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0079","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2009.05.005","article-title":"[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?","volume":"16","author":"Bartels","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0081","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.28814","article-title":"Glia imaging differentiates multiple system atrophy from Parkinson's Disease: a positron emission tomography study with [(11) C]PBR28 and machine learning analysis","volume":"37","author":"Jucaite","year":"2022","journal-title":"Mov Disord"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0082","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson's disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0083","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.parkreldis.2013.01.017","article-title":"Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes","volume":"19","author":"Kobylecki","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","article-title":"An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28","volume":"32","author":"Owen","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00259-018-3974-7","article-title":"TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis","volume":"45","author":"Unterrainer","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.05.004_bib0086","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bmcl.2011.12.084","article-title":"[(1)(8)F]GE-180: a novel fluorine-18 labelled PET tracer for imaging translocator protein 18 kDa (TSPO)","volume":"22","author":"Wadsworth","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.05.004_bib0087","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s13139-017-0475-8","article-title":"Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases","volume":"51","author":"Alam","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0088","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.116.178996","article-title":"11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in Human brain","volume":"58","author":"Ikawa","year":"2017","journal-title":"J Nucl Med"},{"issue":"22","key":"10.1053\/j.semnuclmed.2025.05.004_bib0089","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1021\/acs.jmedchem.1c01562","article-title":"Synthesis and screening in mice of fluorine-containing PET radioligands for TSPO: discovery of a promising (18)F-labeled ligand","volume":"64","author":"Simeon","year":"2021","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.05.004_bib0090","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.2967\/jnumed.121.263200","article-title":"Imaging neuroinflammation in neurodegenerative disorders","volume":"63","author":"Masdeu","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0091","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2967\/jnumed.119.229443","article-title":"Neuroinflammation PET imaging: current opinion and future directions","volume":"61","author":"Jain","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0092","doi-asserted-by":"crossref","DOI":"10.1177\/1536012118792317","article-title":"Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO","volume":"17","author":"Narayanaswami","year":"2018","journal-title":"Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.05.004_bib0093","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/mds.29117","article-title":"Cannabinoid receptor type 1 in Parkinson's Disease: a positron emission tomography study with [(18) F]FMPEP-d(2)","volume":"37","author":"Ajalin","year":"2022","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.807435","article-title":"Imaging of reactive astrogliosis by positron emission tomography","volume":"16","author":"Harada","year":"2022","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.05.004_bib0095","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/00004728-199109000-00013","article-title":"FDG-PET in the selection of brain lesions for biopsy","volume":"15","author":"Hanson","year":"1991","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0096","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fnagi.2019.00249","article-title":"PET imaging of astrogliosis and tau facilitates diagnosis of parkinsonian syndromes","volume":"11","author":"Schonecker","year":"2019","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.05.004_bib0097","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson's Disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.05.004_bib0098","doi-asserted-by":"crossref","first-page":"9787","DOI":"10.3390\/ijms24129787","article-title":"Imidazoline-I2 PET tracers in neuroimaging","volume":"24","author":"Parker","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.05.004_bib0099","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/brain\/awz260","article-title":"Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study","volume":"142","author":"Wilson","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.05.004_bib0100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00259-021-05640-5","article-title":"PET imaging of reactive astrocytes in neurological disorders","volume":"49","author":"Liu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.05.004_bib0101","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3390\/antiox12071411","article-title":"Neuroinflammation and mitochondrial dysfunction in Parkinson's Disease: connecting neuroimaging with pathophysiology","volume":"12","author":"Pizarro-Galleguillos","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.05.004_bib0102","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/syn.21584","article-title":"Detection of ischemic neuronal damage with [(1)(8)F]BMS-747158-02, a mitochondrial complex-1 positron emission tomography ligand: small animal PET study in rat brain","volume":"66","author":"Fukumoto","year":"2012","journal-title":"Synapse"},{"issue":"6566","key":"10.1053\/j.semnuclmed.2025.05.004_bib0103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.abc6108","article-title":"Identification of a choroid plexus vascular barrier closing during intestinal inflammation","volume":"374","author":"Carloni","year":"2021","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2025.05.004_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.593026","article-title":"Blood-brain barrier leakage is increased in Parkinson's disease","volume":"11","author":"Al-Bachari","year":"2020","journal-title":"Front Physiol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0105","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1007\/s00415-021-10411-1","article-title":"Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia","volume":"268","author":"Fujita","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.05.004_bib0106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.parkreldis.2007.11.007","article-title":"Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease","volume":"14","author":"Bartels","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"17","key":"10.1053\/j.semnuclmed.2025.05.004_bib0107","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1073\/pnas.1721694115","article-title":"beta-amyloid accumulation in the human brain after one night of sleep deprivation","volume":"115","author":"Shokri-Kojori","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.05.004_bib0108","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2967\/jnumed.116.187211","article-title":"Cerebrospinal fluid clearance in Alzheimer disease measured with dynamic PET","volume":"58","author":"de Leon","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T20:56:20Z","timestamp":1766782580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0001299825000613"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.05.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Targets for Positron Emission Tomography Imaging in Parkinson\u00b4s Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}